This is a working overview of Albumin binding, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-03-06 and is reviewed periodically as new material appears.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Silencing systemin did not affect the ability of black nightshade to resist herbivory and, when competing against normal plants, silenced plants produced more above-ground biomass and berries. Upon herbivory, systemin was down-regulated in black nightshade in contrast to the other peptides which are up-regulated after herbivory. By contrast HypSys were up-regulated and activated the synthesis of protease inhibitors. The down-regulation of systemin was associated with increased root mass but did not decrease shoot mass, demonstrating that systemin can cause developmental changes as a result of herbivory, allowing the plant to tolerate, rather than directly resist attack. Tomato roots were also affected by tomato systemin, with root growth increasing at high tomato systemin concentrations. By allocating more resources to the roots, plants under attack are thought to store carbon and then use it to re-grow when the attack ends. Overexpressing AtPEP1 also increased root and shoot biomass in A. thaliana.
On 12 June 1944 U.S. carriers made air strikes on the Marianas, convincing Admiral Soemu Toyoda that the U.S. was preparing to invade. This move came as a surprise; the Japanese had expected the next U.S. target to be further south, either at the Carolines or the Palaus, and had protected the Marianas with only 50 land-based aircraft. On 13–15 June, American carriers made additional airstrikes while surface forces bombarded the Marianas. On 15 June, the first American troops went ashore on Saipan. Since control of the Marianas would bring American strategic bombers within range of the Japanese home islands, the IJN decided it was time for the long-awaited Kantai Kessen (decisive battle). Toyoda immediately ordered a fleet-based counterattack, committing nearly all of the Japanese navy's serviceable ships. The main portions of the fleet rendezvoused on 16 June in the western part of the Philippine Sea and completed refueling on 17 June. Admiral Jisaburō Ozawa commanded this force from his newly commissioned flagship, Taihō. In addition to extensive command facilities, reinforced torpedo blisters and a large air group, Taihō was the first Japanese carrier with an armor-plated flight deck, designed to withstand bomb hits with minimal damage. At 18:35 on 15 June the submarine USS Flying Fish sighted a Japanese carrier and battleship force coming out of the San Bernardino Strait. An hour later USS Seahorse spotted a battleship and cruiser force steaming up from the south, 200 miles (320 km) east of Mindanao.
=== Fish similar in appearance === Northern snakeheads (Channa argus) are commonly mistaken for bowfin because of similarities in appearance, most noticeably their elongated, cylindrical shape and long dorsal fin that runs along their backs. Northern snakeheads are piscivorous fish native to the rivers and estuaries of China, Russia, and Korea that have been introduced and become established in parts of North America. Unlike bowfin, which are native to North America, though, the northern snakehead is considered an invasive species and environmentally harmful there. Some contrasting differences in bowfin include a black eyespot on their caudal peduncle, a tan and olive coloration, a shorter anal fin, a more rounded head, pelvic fins at a greater distance from the pectoral fins than in the northern snakehead, and the presence of the gular plate on the ventral side of the lower jaw. Another noticeable difference is that bowfin scales do not continue uniformly from their body to their head. Bowfin heads are smooth and free of scales, whereas the northern snakehead has scales that uniformly continue from its body through to its head. The burbot (Lota lota), a predatory fish native to streams and lakes of North America and Eurasia, is also commonly mistaken for bowfin. Burbots can be distinguished by their flat head and chin barbel, long anal fin, and pelvic fins situated beneath the pectoral fins.
Sources: en.wikipedia.org
Food and Drug Administration (FDA) released an alert concerning abacavir and abacavir-containing medications on 24 July 2008, and the FDA-approved drug label for abacavir recommends pre-therapy screening for the HLA-B*5701 allele and the use of alternative therapy in subjects with this allele. Additionally, both the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group recommend use of an alternative therapy in individuals with the HLA-B*5701 allele.
== History == The drug was developed by Takeda. It got US and European orphan drug status for multiple myeloma in 2011, and for AL amyloidosis in 2012. Takeda submitted a US new drug application for multiple myeloma in July 2015. In September 2015, the U.S. Food and Drug Administration (FDA) granted ixazomib combined with lenalidomide and dexamethasone a priority review designation for multiple myeloma. On 20 November 2015, the FDA approved this combination for second-line treatment. The request for marketing authorisation in Europe was initially refused by the European Medicines Agency (EMA) in May 2016 due to insufficient data showing a benefit of treatment. After Takeda requested a re-examination, the EMA granted a marketing authorisation on 21 November 2016 on the condition that further efficacy studies be conducted. The approval indication is the same as in the US.
Portal 2 was released as a standalone game in April 2011 on both computers and consoles. It is considered one of the greatest video games of all time by numerous publications and critics. It received acclaim for its gameplay, pacing, dark humor, writing, the voice work of McLain, Merchant, and Simmons, and its challenging but surmountable learning curve.
Sources: en.wikipedia.org
=== Neurology === The trigeminal V1 (fifth cranial) nerve bears the sensory pathway of the tear reflexes. When the trigeminal nerve is cut, tears from reflexes will stop, while emotional tears will not. The great (superficial) petrosal nerve from cranial nerve VII provides autonomic innervation to the lacrimal gland. It is responsible for the production of much of the aqueous portion of the tear film.
Meropenem solutions should not be frozen. Somewhat paradoxically, while meropenem is designed to resist bacterial enzymes, it can still be broken down by water. Specifically, the amide bond in the β-lactam ring of meropenem makes it resistant to many β-lactamases (penicillinases), which are bacterial enzymes that can break down penicillin and related antibiotics such as meropenem. Meropenem’s resistance is due to the stability of the β-lactam ring, which is less susceptible to hydrolysis by these enzymes. However, meropenem can undergo hydrolysis in aqueous solutions, which can reduce its effectiveness. Hence meropenem requires prolonged slow administration, or frequent re-administration, to continually replace what has been hydrolyzed by the water component of blood. Meropenem is administered every 8 hours. Dosing must be adjusted for altered kidney function and for haemofiltration. Studies describe application of meropenem therapeutic drug monitoring (measurements of drug levels in the bloodstream at specific intervals) for optimal application. As with other β-lactams antibiotics, the effectiveness of treatment depends on the amount of time during the dosing interval that the meropenem concentration is above the minimum inhibitory concentration for the bacteria causing the infection. For β-lactams, including meropenem, prolonged intravenous administration is associated with lower mortality compared to bolus intravenous infusion, especially in severe infections or those caused by less sensitive bacteria, such as Pseudomonas aeruginosa.
== External links == Gastric+inhibitory+polypeptide at the U.S. National Library of Medicine Medical Subject Headings (MeSH) King MW (16 November 2006). "Gastrointestinal Hormones and Peptides". Indiana University – Purdue University Indianapolis School of Medicine. Archived from the original on 6 December 2007. Retrieved 1 October 2006. Overview of all the structural information available in the PDB for UniProt: P09681 (Gastric inhibitory polypeptide) at the PDBe-KB.
The current epidemic of opioid abuse is the most lethal drug epidemic in U.S. history. The crisis can be distinguished by waves of opioid overdose deaths as described by the Centers of Disease Control and Prevention. The first wave began in the 1990s, related to the rise in prescriptions of natural opioids (such as codeine and morphine), semisynthetic opioids (oxycodone, hydrocodone, hydromorphone, and oxymorphone), and synthetic opioids like methadone. In the U.S., "the age-adjusted drug poisoning death rate involving opioid analgesics increased from 1.4 to 5.4 deaths per 100,000 population between 1999 and 2010". The second wave dates to around 2010 with the rapid increase in opioid overdoses due to heroin. By this time, there were already four times as many deaths by overdose than in 1999. The age-adjusted drug poisoning death rate involving heroin doubled from 0.7 to 1.4 deaths per 100,000 people between 1999 and 2011 and continued to increase to 4.1 in 2015. The third wave of overdose deaths began in 2013, related to synthetic opioids, particularly illicitly produced fentanyl. While the illicit fentanyl market has continuously changed, the drug is generally sold as an adulterant in heroin. Research suggests that the rapid increase of fentanyl into the illicit opioid market has been largely supply-side-driven and dates to 2006.
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.